CSNK1A1 and medulloblastoma: Furthermore, our data also showed that not only CK1-specific small-molecule inhibitors, but also peptides specifically blocking the interaction between CK1 and DDX3X (or other reagents mimicking this effect) could be considered as a therapeutic option for medulloblastoma or other tumors sharing this mutational signature.